U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025Company ...
Travere Therapeutics, Inc., announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) ...
Materials for energy and catalysis are materials with electrochemical properties that makes them suitable for use in energy storage applications, such as batteries, and electrocatalysts. Instability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback